XBiotech Announces Enrollment Completion, Positive Findings for Bermekimab in Pancreatic Cancer Study

NEXT STORY
Progenics Pharmaceuticals Sets First Quarter 2019 Financial Results and Business Update Call for May 9
PREV STORY
Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

5th Annual Translational Microbiome Conference – Boston, United States – April 16th-18th, 2019

Dublin, Feb. 13, 2019 (GLOBE NEWSWIRE) -- The "5th Annual Translational Microbiome Conference - ...

author_avatar
NASDAQ Market News

VBL Therapeutics Announces Appointment of Dr. Rachel W. Humphrey to Head of the Scientific Advisory Board

TEL AVIV, Israel, June 21, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage ...

author_avatar
NASDAQ Market News

Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance

LOS ANGELES, May 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter ...

author_avatar
NASDAQ Market News